1,069 reports of this reaction
2.0% of all CEFTRIAXONE reports
#6 most reported adverse reaction
DYSPNOEA is the #6 most commonly reported adverse reaction for CEFTRIAXONE, manufactured by B. Braun Medical Inc.. There are 1,069 FDA adverse event reports linking CEFTRIAXONE to DYSPNOEA. This represents approximately 2.0% of all 52,413 adverse event reports for this drug.
Patients taking CEFTRIAXONE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for CEFTRIAXONE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for CEFTRIAXONE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,069 FDA reports for CEFTRIAXONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.0% of all adverse event reports for CEFTRIAXONE, making it a notable side effect.
If you experience dyspnoea while taking CEFTRIAXONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.